Northwest Bio Initiates Phase III DCVax-L Trial In Germany - Quick Facts

(RTTNews) - Northwest Biotherapeutics (NWBOW, NWBO, NWBS.L) announced it has initiated the Phase III trial of DCVax-L in Germany. The company said the first German site is now starting to screen patients for purposes of enrollment. The company has scheduled the full-day site initiations for 3 more sites during June and 4 further sites in July.

Linda Powers, CEO of NW Bio, said: "We are excited to have the Phase III DCVax-L trial open for enrollment in Germany. It has taken a major team effort to accomplish the steps required for these sites. However, we are now ready to initiate a substantial set of clinical trial sites throughout Germany, and we have built a strong foundation for our clinical programs in Germany."

The trial has been enrolling in parallel in the US and Europe (in the UK), as previously announced, the company noted.